Tonix Pharmaceuticals CEO Seth Lederman joins Natalie Stoberman from the Proactive studio to discuss the latest results from the molecular mechanism of action of tianeptine, the active ingredient of TNX-601 ER, and how its impacting patients in the in Phase 2 clinical development for the treatment of major depressive disorder.
Lederman says the study has shown promising results in treating depression without affecting neurotransmitter levels. He explains that the study interacts with the PPAR protein in the nuclei of neurons and glia cells, facilitating the restoration of connections in the brain. Lederman adds this discovery could revolutionize the understanding and treatment of depression. Tonix Pharmaceuticals is now focused on advancing TNX-601 to make it available to depressed patients in the United States.
Contact DetailsProactive Studio
+1 347-449-0879
